Biotech firm Paratus Sciences emerged from stealth with a $100M Series A funding round.
The firm intends to develop a drug discovery platform to solve inflammation, viral infection, and other illnesses by studying the biology of bats.
Paratus is led by CEO Amir Nashat, who previously led projects at Dewpoint Therapeutics and Kojin Therapeutics.
- In order to overcome the negative perception of conducting research on bats and tampering with their biology, the company remained in stealth over the last year.
- Given the current challenging climate for biotech companies, the business is open to partnerships in the future.
- Polaris Partners, Arch Venture Partners, ClavystBio, EcoR1 Capital, and Leaps by Bayer co-led the current financing, with participation from Alexandria Venture Investments.
